Medical professional requires transition from favipiravir to more practical molnupiravir

A leading well being skilled says Thailand should part out the utilization of favipiravir, saying molnupiravir is a more effective Covid-19 remedy. Dr Opass Putcharoen, from the Thai Red Cross Emerging Infectious Diseases Clinical Centre, says this shall be important as the nation strikes to declaring Covid-19 endemic. He added that the value of molnupiravir produced in India is somewhere between 600 and seven-hundred baht per treatment course, compared to 50,000 baht for the molnupiravir version produced by Merck.
According to a Bangkok Post report, the Public Health Ministry has beforehand stated that a course of favipiravir costs around 1,000 baht, whereas a molnupiravir treatment course prices 10,000 baht. Earlier this week, Cabinet gave the go-ahead to ditch a procurement plan for 50,000 doses of molnupiravir, in favour of 17 million favipiravir pills and 5,166 vials of the antiviral medication, remdesivir.
Opass factors out that whereas favipiravir has been the main remedy of alternative in Thailand, there is no clear data that proves its efficacy. By distinction, a latest study reveals that molnupiravir is 30% efficient at stopping extreme sickness in Covid-19 sufferers. The medic is looking on the federal government to import molnupiravir from India and ensure all hospitals have adequate provides, so it may be administered promptly to those that need it.
He goes on to say that sure classes of Covid-19 sufferers are nonetheless vulnerable to severe sickness, even when they’re absolutely vaccinated. Triple on immunosuppressive drugs, who want entry to efficient treatment. He adds that whereas new infections are expected to drop 2 – three weeks after the Songkran vacation, the virus still must be closely monitored..g

Leave a Comment